Single-cell analysis and construction of a regenerative-inducing medicine database
First written in FY2019. 2 of 5 entries say "Advanced", first in FY2020. Latest entry: FY2025.
1 other company's latest entry also says "Restated".
- FY2025RestatedAnnual report
「At present, both in Japan and globally, facilities capable of comprehensive gene expression analysis and comprehensive gene structure analysis at the single-cell level are limited to a small number of large-scale research institutions, such as the NIH (National Institutes of Health). We are convinced that possessing this technology at the venture-company level demonstrates that our drug discovery and development technology can compete globally.」
The policy of establishing single-cell analysis technology, applying it to drug discovery and safety assessment, and sharing it externally is being reaffirmed. - FY2024AdvancedAnnual report
「At present, both in Japan and globally, facilities capable of comprehensive gene expression analysis and comprehensive gene structure analysis at the single-cell level are limited to a small number of large-scale research institutions, such as the NIH (National Institutes of Health). We are convinced that possessing this technology at the venture-company level demonstrates that our drug discovery and development technology can compete globally. Going forward, in addition to applying the technology to our own drug discovery research, we plan to share it with academic researchers and pharmaceutical companies in Japan and overseas. This will make a significant contribution to improving the probability of successful drug discovery and development and to the assessment of safety and efficacy in Japan and overseas, while enabling us to advance the development of the world's first regenerative medicine® that safely maximizes the tissue-regenerative effects of tissue stem cells.」
In addition to establishing single-cell analysis technology and building a database, the policy for applying and sharing the technology with academia and pharmaceutical companies for drug discovery and safety assessment is becoming more concrete. - FY2022RestatedAnnual report
「The Company and Osaka University are currently building a detailed database of comprehensive gene expression changes and comprehensive gene structural changes induced in individual cells of organs and tissues in vivo by first-, second- and third-generation regeneration-inducing medicines.」
The initiative to build a single-cell-level analysis database for first- to third-generation regenerative medicine products is being reaffirmed. - FY2020AdvancedAnnual report
「The Company is conducting joint research with Osaka University on gene expression analysis and comprehensive gene structure analysis at the single-cell level of mesenchymal stem cells in vivo and has established the relevant technologies.」
The technologies for gene expression and structural analysis at the single-cell level have been established, and the accumulation of database information on first- through third-generation regeneration-inducing medicines is under way. - FY2019First statedAnnual report
「The Company and Osaka University are currently building a detailed database of comprehensive gene expression changes and comprehensive gene structural changes induced in individual cells of organs and tissues in vivo by first-, second- and third-generation regeneration-inducing medicines.」
A database is being built of gene expression and structural changes at the single-cell level for first- through third-generation regeneration-inducing medicines.